1. Huganpian, a traditional chinese medicine, inhibits liver cancer growth in vitro and in vivo by inducing autophagy and cell cycle arrest
- Author
-
Xiaohong Pan, Shayan Chen, Yuyang Wang, Miaomiao Yan, Yuxin Li, Hongliu Sun, Yansong Wang, and Xue Gao
- Subjects
0301 basic medicine ,Huganpian ,Cell cycle checkpoint ,Apoptosis ,RM1-950 ,Cell cycle ,Resting Phase, Cell Cycle ,03 medical and health sciences ,Mice ,0302 clinical medicine ,In vivo ,Cell Line, Tumor ,Autophagy ,Medicine ,Animals ,Humans ,Medicine, Chinese Traditional ,Tumor growth ,Cell Proliferation ,Pharmacology ,biology ,Kinase ,business.industry ,Cyclin-dependent kinase 2 ,Cyclin-Dependent Kinase 2 ,Liver Neoplasms ,G1 Phase ,Cyclin-Dependent Kinase 4 ,General Medicine ,Cell Cycle Checkpoints ,Hep G2 Cells ,medicine.disease ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cancer research ,biology.protein ,Therapeutics. Pharmacology ,business ,Liver cancer ,Drugs, Chinese Herbal - Abstract
Huganpian (HGP), a traditional chinese medicine composed of 6 herbs, possesses excellent therapeutic effects in clinical application. In this study, we aimed to elucidate the anti-tumor activity and the underlying mechanisms of HGP in liver cancer. The results of this study indicated that HGP effectively inhibited liver cancer growth in vitro and in vivo in a dose-dependent manner. Mechanistically, HGP exerted its anti-tumor effects by triggering autophagy with increased LC3Ⅱ and beclin1 levels and arrested the cell cycle on G0-G1 phase by downregulating the expressions of cyclin-dependent kinase 2 (CDK2), cyclin-dependent kinase 4 (CDK4) and cyclinE1 in vitro and in vivo. Meanwhile, HGP did not induce apoptosis significantly. Importantly, we also confirmed that there were fewer side effects of HGP on immune system. Taken together, our findings suggest for the first time that HGP may become a promising drug or adjuvant drug with a lower toxicity for liver cancer treatment in the future.
- Published
- 2019